NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922

ALK is involved in the onset of several tumors. Crizotinib (Xalkori(TM)), a potent ALK inhibitor, represents the current front-line treatment for ALK+ NSCLC and shows great clinical efficacy. However, resistant disease often develops after initial response. ASP3026 is a novel second-generation ALK i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Mologni, Luca, Ceccon, Monica, Pirola, Alessandra, Chiriano, Gianpaolo, Piazza, Rocco, Scapozza, Leonardo, Gambacorti-Passerini, Carlo
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2015
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467397/
https://ncbi.nlm.nih.gov/pubmed/25749034
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares